Regeneron Pharmaceuticals REGN
F. Ryan Arthur (Director) plans to sell 400 REGN shares, about $314,204
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0001968582-26-000093
- Approximate sale date: Feb 9, 2026
- Broker: J.P. Morgan Securities LLC
- Shares acquired by: Compensation
- 10b5-1 plan adopted: Oct 31, 2025
All of F. Ryan Arthur's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 1 shares at $775.63 on Feb 9, 2026 · Form 4
- Sold 10 shares at $776.59 on Feb 9, 2026 · Form 4
- Sold 57 shares at $777.56 on Feb 9, 2026 · Form 4
- Sold 12 shares at $778.53 on Feb 9, 2026 · Form 4
- Sold 5 shares at $779.41 on Feb 9, 2026 · Form 4
- Sold 1 shares at $780.09 on Feb 9, 2026 · Form 4
- Sold 5 shares at $781.48 on Feb 9, 2026 · Form 4
- Sold 1 shares at $782.53 on Feb 9, 2026 · Form 4
- Sold 3 shares at $783.34 on Feb 9, 2026 · Form 4
- Sold 1 shares at $784.59 on Feb 9, 2026 · Form 4
- Sold 1 shares at $785.71 on Feb 9, 2026 · Form 4
- Sold 2 shares at $786.29 on Feb 9, 2026 · Form 4
- Sold 1 shares at $787.82 on Feb 9, 2026 · Form 4
- Sold 7 shares at $777.46 on Mar 2, 2026 · Form 4
- Sold 2 shares at $778.3 on Mar 2, 2026 · Form 4
- Sold 5 shares at $779.69 on Mar 2, 2026 · Form 4
- Sold 3 shares at $780.69 on Mar 2, 2026 · Form 4
- Sold 2 shares at $781.21 on Mar 2, 2026 · Form 4
- Sold 2 shares at $782.62 on Mar 2, 2026 · Form 4
- Sold 10 shares at $783.62 on Mar 2, 2026 · Form 4
- Sold 9 shares at $784.48 on Mar 2, 2026 · Form 4
- Sold 11 shares at $785.48 on Mar 2, 2026 · Form 4
- Sold 7 shares at $786.61 on Mar 2, 2026 · Form 4
- Sold 2 shares at $787.34 on Mar 2, 2026 · Form 4
- Sold 20 shares at $788.96 on Mar 2, 2026 · Form 4
- Sold 20 shares at $789.28 on Mar 2, 2026 · Form 4
- Sold 1 shares at $771.32 on Apr 1, 2026 · Form 4
- Sold 3 shares at $772.76 on Apr 1, 2026 · Form 4
- Sold 8 shares at $773.59 on Apr 1, 2026 · Form 4
- Sold 8 shares at $774.58 on Apr 1, 2026 · Form 4
- Sold 14 shares at $775.58 on Apr 1, 2026 · Form 4
- Sold 13 shares at $776.62 on Apr 1, 2026 · Form 4
- Sold 9 shares at $777.42 on Apr 1, 2026 · Form 4
- Sold 4 shares at $778.24 on Apr 1, 2026 · Form 4
- Sold 40 shares at $779.71 on Apr 1, 2026 · Form 4
- Sold 5 shares at $701.76 on May 1, 2026 · Form 4
- Sold 15 shares at $702.46 on May 1, 2026 · Form 4
- Sold 24 shares at $703.46 on May 1, 2026 · Form 4
- Sold 15 shares at $704.28 on May 1, 2026 · Form 4
- Sold 14 shares at $705.56 on May 1, 2026 · Form 4
- Sold 7 shares at $706.74 on May 1, 2026 · Form 4
- Sold 4 shares at $707.4 on May 1, 2026 · Form 4
- Sold 6 shares at $709.45 on May 1, 2026 · Form 4
- Sold 2 shares at $710.87 on May 1, 2026 · Form 4
- Sold 5 shares at $711.49 on May 1, 2026 · Form 4
- Sold 1 shares at $712.09 on May 1, 2026 · Form 4
- Sold 2 shares at $714.13 on May 1, 2026 · Form 4
Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Zoetis ZTS public float $69.2B, Jun 30, 2025
- Idexx Laboratories IDXX public float $42.9B, Jun 30, 2025
- Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025
- Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
- Gilead Sciences GILD public float $103.2B, Jun 30, 2025
